Xeber.world
FDA Commissioner Marty Makary resigns after months of internal scrutiny, with Kyle Diamantas stepping in as acting commissioner. Meanwhile, Eli Lilly'...
Hims & Hers Health Inc. (Hims) incurred a $33 million non-cash impairment charge in Q2 2024 due to its strategic pivot toward GLP-1 weight loss medica...
A new Rice University study finds that people who lose weight using GLP-1 medications like Ozempic face greater judgment than those who regain weight...
Novo Nordisk’s new weight-loss pill, Wegovy, has achieved 1.3 million prescriptions in Q1 2026, prompting the company to raise its full-year guidance....
Novo Nordisk revised its 2024 sales and operating profit guidance upward following strong performance of its Wegovy obesity drug. The Danish pharma gi...
Medicare will launch a pilot program in July 2026 offering GLP-1 weight loss drugs like Wegovy and Zepbound for $50 per month. The initiative, running...
France’s medicines regulator has fined Novo Nordisk $2 million and Eli Lilly $127,000 for allegedly misleading advertisements for their weight loss dr...
The FDA proposed excluding semaglutide and tirzepatide from compounding lists, citing no clinical need. Katherine Szarama was named acting director of...
The FDA has proposed excluding semaglutide and tirzepatide, key ingredients in popular weight-loss and diabetes drugs like Wegovy, Ozempic, Mounjaro,...
The Trump administration's Medicare obesity drug pilot was abandoned after insurers declined to participate. Meanwhile, Amazon's One Medical is launch...
A new study reveals that discontinuing GLP-1 medications such as Ozempic or Wegovy can reverse their cardiovascular benefits within six months. Resear...
A large Swedish study published in The Lancet Psychiatry suggests GLP-1 receptor agonists like Ozempic and Wegovy may lower the risk of worsening depr...
The FDA has approved a 7.2 mg weekly dose of Wegovy, a GLP-1 medication, for weight loss. Clinical trials show this higher dose can lead to 25% more w...
New research reveals that around 10% of people may have genetic variations causing 'GLP-1 resistance,' reducing the effectiveness of popular weight lo...